isolates were also tested on 7H10 Middlebrook agar for susceptibility to aminosalicylic acid, ethionamide, capreomycin, clarithromycin, and ofloxacin (6) . No effective medical treatment was available for these patients. In 2 of the hospitals affected, all patients died, with a short survival time (median of 44 and 49.5 days for the 2 hospitals) between diagnosis and death (6,7). A high rate of reinfection (45%) also was noted among HIV-positive patients treated with anti-TB drugs (7). As a result of this outbreak, Spanish hospitals now implement exhaustive control measures, such as maintaining respiratory isolation units under negative pressure; in addition, a national surveillance network for MDR TB was set up in Spain in 1998. From 1998 through 2003, we detected 22 new cases of infection with this strain (10), but no new cases have since been reported to the national MDR TB database.
Our experience indicates that the implementation of more stringent control measures and the use of new, more effective treatments for HIV infection can help to bring XDR TB outbreaks under control in developed countries. However, the outlook is bleak for developing countries like South Africa, in which coinfection with HIV and a highly transmissible and untreatable XDR TB strain could amplify the TB problem to levels unprecedented since the advent of antimicrobial drugs. These countries urgently require assistance with the establishment of control measures and the development of new drugs and effective vaccines against TB.
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Transfusionassociated Hepatitis E, France
To the Editor: Hepatitis E virus (HEV) is a leading cause of acute and fulminant hepatitis in developing countries (1). In industrialized countries, HEV seroprevalence rates of 0.4%-3% are common, and evidence is mounting that autochthonous transmission might account for a substantial proportion of infections (1-3). Whereas fecal-oral HEV transmission is preponderant in developing countries, other routes have been demonstrated in industrialized countries, among them consumption of pork or boar meat (1,4). Parenteral transmission was first suggested but not demonstrated (5,6). Because viruses cannot be fully inactivated in blood products, HEV recently emerged as a transfusion-transmitted pathogen, with 6 reported cases, including 3 in which comparative analysis of HEV sequences from blood donor and recipient was performed (7). We describe what is, to our knowledge, the first case in France and the first case worldwide involving a child as blood recipient. Serum samples taken from 12 U of blood products that the child received during the 3-month period before onset of hepatitis were tested for HEV RNA; 1 sample was positive. Concentrated erythrocytes (310 mL) from this positive blood donation were transfused to the child in May 2006, 4 weeks after collection and 6 weeks before acute hepatitis developed. HEV IgG and IgM antibodies were not detected in the blood donation, which indicates that the blood donation occurred during the prodromic phase of HEV disease. HEV nucleotide sequences from the blood donor and recipient were identical. Phylogenetic analysis showed that they clustered together and were closely related to genotype 3f, which is prevalent in Europe (Figure [8]) .
The blood donor was a 24-yearold man. He did not travel outside metropolitan France for 8 months before donating blood. Anti-HEV IgG seroconversion was observed on a serum sample collected 24 weeks after blood donation, whereas anti-HEV IgM and serum HEV RNA tested negative. ALT levels were within normal values at the time of blood donation and 24 weeks later. No clinical signs were reported at any time. No other recipient received blood products from this donor.
Our data show that HEV was transmitted from 1 blood donor to the recipient child. On the basis of retrospective HEV RNA detection, 6 other transfusion-transmitted HEV infections, all involving adult blood recipients, have occurred in HEV-hyperendemic and industrialized countries (7). Transfusion-transmitted HEV strains belonged to different genotypes/subtypes that corresponded to those found in the same geographic areas (Figure) .
In France, neither HEV antibodies nor HEV RNA are systematically tested in blood donors, and blood donations currently are not tested for ALT. In the absence of systematic HEV RNA testing, HEV diagnosis in blood donations may be hampered by HEV viremia before clinical onset and anti-HEV seroconversion, the possible short persistence or absence of HEV antibodies, and the high frequency of subclinical infections
